Hi! I'm Justin - I run Taimaka. We're an EA org, but pretty quiet on the forum - keep meaning to get around to writing up something about our work, but hasn't happened yet, so this is a good excuse to say hello!
This is a good question, and our cost-per-life-saved figure is also obviously a bold claim, so I'll share a bit about our thinking here. One disclaimer I'll make for clarity is that while our work is supported by GiveWell, our cost-effectiveness model is our own and the thoughts I'm sharing here are my own - I don't speak for GiveWell's team and their views. Our CEA is built off of their past work on acute malnutrition, but the end results + claims are ours.
Generally, the way I think about our model and our $1.6k per life saved estimate is that this is the most accurate + true estimate we have for our program, but that you should probably read this estimate as having higher error bars surrounding it than estimates for current GiveWell top charities. I think there are two primary reasons for this:
Hopefully this is helpful! In summary: we take this figure seriously, and stand by our modeling. We haven't put our thumb on the scales anywhere to make this number lower, it's the true result of a good faith effort to adapt GiveWell's model of other acute malnutrition treatment programs to our own. That said, expect higher error bars in this than you would in models for current top charities, both because of vagaries in Taimaka being younger + because of limitations in what we currently know about acute malnutrition treatment. If you're willing to accept that higher level of risk, I think Taimaka is a great donation option to do a lot of good, potentially even more cost-effectively than other places. Happy to have a call to chat this through in more detail if you'd like, feel free to shoot me an email! (My first name at taimaka.org).
Thanks for posting this Madeleine, it is great to see people from outside the traditional EA global health space engaging here!
This isn't an area I'm super familiar with, but I'll try to throw in some questions/thoughts to perhaps draw out the argument a bit, because I think this is valuable to think about!
Let's assume for the sake of discussion here that the creation of a CHW program in an area where core CHW-delivered care (like vaccination, malaria bed nets, SMC, vitamin A, deworming, etc.) is completely unavailable is cost-effective at a typical EA bar.
I think it is interesting that the recommended thing to get funded notably slightly different/more indirect, which is to fund policy change to get governments to pay for the creation of more professional CHW programs. I think I'd be really interested in hearing more about the evidence base behind this recommendation (e.g., the systematic review you linked pertains more to academic/NGO interventions designed to improve CHW performance, rather than efforts to improve government rollout of CHWs). Questions I'd be really interested in hearing some more about:
I think it is then interesting to revisit our assumption at the top here. The counterfactual we're talking about here is probably not zero treatment to CHW treatment. It probably looks more like a reasonably competent government rolls out CHWs in an area that has some existing primary healthcare services - in this situation, how many more people get treatment? At what marginal additional cost? Is that marginal benefit worth that cost?
Anyway in closing - you guys should put together an EA-style CEA of this! I think that'd be the best way to make this case.